嘉事堂药业股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.msf.gov.cn）"进行查验。 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.msf.gove.n）"进行查验。 【 立信会计师事务所(特殊普通合伙) BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 关于嘉事堂药业股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZB10875 号 嘉事堂药业股份有限公司全体股东: 我们审计了嘉事堂药业股份有限公司(以下简称"嘉事堂公 司")2024 年度的财务报表,包括 2024 年 12 月 31 目的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注,并于 2025 年 4 月 25 日出具了报告号为信会师报字(2025)第 ZB10874 号的 无保留意见审计报告。 嘉事堂公司管理层根据中国证券 ...

嘉事堂药业股份有限公司 内部控制审计报告 2024 年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查询 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.cor.cn）"进行查询 " " " 工信会计师事务所(特殊普通合伙) HINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTAN 内部控制审计报告 信会师报字[2025]第 ZB10873 号 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定,建立健全和有效实施内部控制,并评 价其有效性是嘉事堂董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的 有效性发表审计意见,并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。 此外,由于情况的变化可能导致内部控制变得不恰当,或对控制政策 和程序遵循的程度降低,根据内部控制审计结果推测未来 ...

2024 年度独立董事述职报告 作为嘉事堂药业股份有限公司（以下简称"嘉事堂"或"公司"）第七届董 事会独立董事，报告期内，本人严格按照《公司法》《证券法》《上市公司独立董 事管理办法》《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公 司章程》、《独立董事工作制度》等内部制度的规定和要求，勤勉尽责地履行独立 董事的职责和义务，审慎认真地行使公司和股东赋予的权利，积极参加股东大会、 董事会、独立董事专门会议及董事会专门委员会会议，维护公司整体利益，维护 全体股东尤其是中小股东的合法权益，并在深入了解公司情况的基础上，运用专 业知识和经验履行职责，作为董事会成员对公司重大事项进行决策，为公司发展 提供意见和建议，有效发挥了独立董事的作用。 一、独立董事的基本情况 张海燕，女，会计学博士，现任清华大学经济管理会计系副教授，兼任中汽 研汽车试验场股份有限公司、广州安凯微电子股份有限公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情形。 嘉事堂药业股份有限公司 报告期内，本人作为公司审计委员会成员亲自出席了审计委员会会议，认真 履行职责，根据公司 ...

作为嘉事堂药业股份有限公司（以下简称"嘉事堂"或"公司"）第七届董 事会独立董事，报告期内，本人严格按照《公司法》《证券法》《上市公司独立董 事管理办法》《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公 司章程》、《独立董事工作制度》等内部制度的规定和要求，勤勉尽责地履行独立 董事的职责和义务，审慎认真地行使公司和股东赋予的权利，积极参加股东大会、 董事会、独立董事专门会议及董事会专门委员会会议，维护公司整体利益，维护 全体股东尤其是中小股东的合法权益，并在深入了解公司情况的基础上，运用专 业知识和经验履行职责，作为董事会成员对公司重大事项进行决策，为公司发展 提供意见和建议，有效发挥了独立董事的作用。 嘉事堂药业股份有限公司 2024 年度独立董事述职报告 一、独立董事的基本情况 熊焰，男，管理学硕士，曾任北京金融资产交易所有限公司董事长，现任北 京国富资本有限公司董事长。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情形。 二、独立董事年度履职情况 （一）参加董事会、股东大会情况 报告期内，本人积极参加公司召开的各次董事会。每次会议召开之前，本 ...

嘉事堂药业股份有限公司董事会 2025 年 4 月 26 日 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等法律法规、规范性文件的要求，嘉事 堂药业股份有限公司董事会就公司在任独立董事熊焰、梁雨、张海燕的独立性情 况进行评估并出具如下专项意见： 经核查在任独立董事熊焰、梁雨、张海燕的任职经历、任职情况等资料，上 述人员符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关规定要求。 嘉事堂药业股份有限公司 董事会关于独立董事独立性自查情况的专项意见 ...

嘉事堂药业股份有限公司 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情形。 二、独立董事年度履职情况 （一）参加董事会、股东大会情况 报告期内，本人积极参加公司召开的各次董事会。每次会议召开之前，本人 均主动了解做出决策所需要的情况和资料，了解公司整体的经营情况。在会议召 开期间，详细听取公司管理层就有关情况的说明，认真审议每项议案，积极参与 讨论并提出合理化建议，并以谨慎的态度在会议上行使表决权。报告期内各次董 事会、专门委员会会议审议的相关议案均未损害全体股东的利益，特别是中小股 东的利益，因此本人均投出赞成票，没有反对、弃权的情况。会议出席情况如下： | | 出席董事会的情况 | | | 出席股东大会的情况 | | --- | --- | --- | --- | --- | | 本报告期应参加 | 现场出席 | 以通讯方式参加 | 委托出席 | 出席股东大会次数 | | 次数 | 次数 | 次数 | 次数 | | | 8 | 1 | 7 | 0 | 1 | （二）参加董事会专门委员会情况 报告期内，本人分别参加了所属专门委员会的会议，不存在无故缺席的情形 ...

Financial Performance - The company's basic earnings per share decreased by 38.46% to 0.1600 yuan in Q1 2025 compared to Q1 2024, which was 0.2600 yuan [1] - Operating revenue dropped by 37.15% to 4.678 billion yuan in Q1 2025 from 7.443 billion yuan in Q1 2024 [1] - Net profit fell by 39.47% to 0.46 billion yuan in Q1 2025, down from 0.76 billion yuan in Q1 2024 [1] - The return on equity decreased by 40.11% to 1.06% in Q1 2025 from 1.77% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 12,516.04 million shares, accounting for 42.95% of the circulating shares, with a change of 30,000 shares from the previous period [1] - China Everbright Medical Health Industry Co., Ltd. remains the largest shareholder with 4,187.64 million shares, representing 14.37% of total share capital [2] - New entrant Shenzhen New Industry Venture Capital Co., Ltd. holds 162.00 million shares, accounting for 0.56% of total share capital [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

Financial Performance - The company's operating revenue for 2024 was ¥24,018,607,695.13, a decrease of 19.93% compared to ¥29,996,240,361.78 in 2023[15] - The net profit attributable to shareholders for 2024 was ¥160,668,362.95, down 35.75% from ¥250,060,041.68 in the previous year[15] - The net profit after deducting non-recurring gains and losses was ¥80,203,887.73, a decline of 66.51% from ¥239,475,788.49 in 2023[15] - The basic earnings per share for 2024 was ¥0.55, representing a decrease of 36.05% compared to ¥0.86 in 2023[15] - The total assets at the end of 2024 were ¥14,037,951,940.30, down 18.01% from ¥17,120,851,592.43 at the end of 2023[15] - The cash flow from operating activities for 2024 was ¥180,355,187.36, a significant decrease of 88.70% from ¥1,595,439,529.42 in 2023[15] - The company reported a significant gain from the disposal of non-current assets, totaling 201.43 million CNY in 2024, compared to 845.56 thousand CNY in 2023[22] - The company reported a net profit of ¥321,674,900, with a significant discrepancy between net profit and cash flow from operating activities[52] Revenue Breakdown - The pharmaceutical wholesale segment generated CNY 22,599,917,803, accounting for 94.09% of total revenue, with a year-on-year decline of 20.23%[40] - Revenue from pharmaceutical logistics increased by 15.79% to CNY 441,324,131.09, while revenue from pharmaceutical retail decreased by 23.94% to CNY 977,365,760.55[40] - The Beijing region contributed CNY 10,999,806,448, which is 45.80% of total revenue, showing a slight decline of 1.40% year-on-year[40] Market Position and Strategy - The company ranked 11th in the national pharmaceutical commercial industry in 2023, indicating a strong market position[26] - The company is focusing on expanding its logistics services to enhance customer stickiness and improve service capabilities[28] - The company is actively participating in the construction of a pension ecosystem, aligning with national strategies to enhance public health services[27] - The company is leveraging digitalization and intelligent governance to strengthen its competitive edge in the pharmaceutical distribution sector[26] - The company is committed to integrating its pharmaceutical and healthcare services with financial services to support business expansion[32] Governance and Management - The company has established an effective performance evaluation and incentive constraint mechanism, which is being gradually improved[91] - The company maintains a complete and independent business system, with no reliance on related transactions with the largest shareholder[95] - The company has a fully independent financial accounting system and management practices, ensuring independent financial decision-making[97] - The board of directors and supervisory board operate independently, ensuring that the interests of minority shareholders are protected[88][89] - The company is committed to maintaining a strong governance structure with independent directors overseeing its operations[115] Shareholder Engagement - The company held its first temporary shareholders' meeting on March 29, 2024, with an investor participation rate of 36.39%[99] - The annual shareholders' meeting for 2023 took place on May 21, 2024, with a participation rate of 36.41%[99] - The second temporary shareholders' meeting for 2024 was held on July 22, 2024, with a participation rate of 40.90%[99] - The third temporary shareholders' meeting for 2024 is scheduled for December 30, 2024, with a participation rate of 40.95%[99] Employee and Workforce - The total number of employees at the end of the reporting period is 1,969, with 1,764 from major subsidiaries and 192 from the parent company[135] - The educational background of employees includes 62 with postgraduate degrees, 744 with bachelor's degrees, 777 with associate degrees, and 386 with high school or lower education[136] - The average tenure of pharmaceutical professionals in the company exceeds 18 years, ensuring a highly specialized workforce[36] Risk Management and Compliance - The company has implemented a risk management approach that includes risk avoidance, reduction, sharing, and acceptance to effectively control risks[150] - The internal control system is designed to ensure compliance with laws and regulations, enhance management levels, and protect investor interests[146] - The company has established a comprehensive internal control system consisting of 13 categories, including financial management, risk management, and internal audit systems[153] Environmental and Social Responsibility - The company actively participated in poverty alleviation efforts, purchasing agricultural products worth approximately 640,000 yuan from targeted assistance counties[176] - The company has established a scientific and efficient environmental management process, adhering to various environmental laws and regulations[174] - The company provided drug delivery services to nearly 2,000 rural health clinics in remote areas, with a total of 2.6055 million deliveries valued at over 400 million yuan[177] Future Outlook and Investments - The company is investing in new technology development, allocating 100 million yuan for R&D in the upcoming year[126] - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[126] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million yuan earmarked for potential deals[126] Dividend Policy - The company has a cash dividend policy that stipulates a minimum of 30% of the annual consolidated net profit for distribution[139] - The proposed cash dividend is 1.7 yuan per 10 shares, amounting to a total cash dividend of 49,590,210.40 yuan, based on a total share capital of 291,707,120 shares[140]

Financial Performance - The company's operating revenue for Q1 2025 was ¥4,677,941,616.65, representing a decrease of 37.15% compared to ¥7,442,979,521.58 in the same period last year[5] - Net profit attributable to shareholders was ¥46,148,136.04, down 38.90% from ¥75,533,309.91 year-on-year[5] - Basic and diluted earnings per share decreased by 38.46% to ¥0.16 from ¥0.26 in the same period last year[5] - The company reported a significant drop in sales revenue from goods and services, which was ¥5,182,797,662.41, down 38.17% from ¥8,382,405,389.24[10] - Total operating revenue for the current period is ¥4,677,941,616.65, a decrease of 37.8% compared to ¥7,442,979,521.58 in the previous period[18] - Net profit for the current period is ¥75,129,771.10, a decline of 36.0% from ¥117,353,880.03 in the previous period[20] - The company recorded a total profit of ¥108,018,431.52 for the current period, down 33.1% from ¥161,576,235.41 in the previous period[19] Cash Flow - The net cash flow from operating activities was negative at -¥43,628,489.73, a decline of 115.85% compared to a positive cash flow of ¥275,331,117.53 in the previous year[5] - Cash flow from operating activities shows a net outflow of ¥43,628,489.73, a significant decrease from a net inflow of ¥275,331,117.53 in the previous period[23] - Investment activities generated a net cash flow of -¥805,348.22, a decline of 109.13% compared to ¥8,818,002.82 in the previous year[11] - The company’s investment activities resulted in a net cash outflow of ¥805,348.22, compared to a net inflow of ¥8,818,002.82 in the previous period[23] - The net increase in cash and cash equivalents was -¥69,216,102.01, a decrease of 220.27% from an increase of ¥57,550,565.79 in the previous year[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥13,517,910,702.30, down 3.70% from ¥14,037,951,940.30 at the end of the previous year[5] - The total current assets amount to ¥12,505,806,134.77, a decrease from ¥13,004,908,179.96 at the beginning of the period, representing a decline of approximately 3.8%[15] - The total liabilities decreased from ¥7,973,111,304.62 to ¥7,378,004,245.45, a reduction of about 7.5%[17] - The cash and cash equivalents at the end of the period are ¥2,124,865,439.22, down from ¥2,223,287,855.91, a decrease of about 4.4%[15] - The accounts receivable decreased from ¥6,878,398,107.65 to ¥6,662,641,442.69, a decline of approximately 3.1%[15] - The inventory increased slightly from ¥2,739,440,537.06 to ¥2,752,875,854.37, an increase of about 0.5%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,619[12] - The top 10 shareholders hold a combined 39.84% of the shares, with China Everbright Medical Health Industry Co., Ltd. holding 14.36% and China Everbright Group Co., Ltd. holding 14.12%[12] Equity and Retained Earnings - The retained earnings at the end of the period are ¥2,561,568,145.45, up from ¥2,515,420,009.41, an increase of approximately 1.8%[17] - The total equity increased from ¥6,064,840,635.68 to ¥6,139,906,456.85, reflecting an increase of about 1.2%[17] Operating Costs and Expenses - Total operating costs for the current period are ¥4,533,042,059.88, down 37.8% from ¥7,289,981,773.84 in the previous period[19] - The company incurred a tax expense of ¥32,888,660.42, compared to ¥44,222,355.38 in the previous period, reflecting a decrease of 25.6%[19] - The company reported a decrease in sales expenses to ¥74,957,767.59 from ¥149,240,297.12, a reduction of 49.7%[19]

股票代码：002462 股票简称：嘉事堂 公告编号：2025-06 一、本次权益变动基本情况 2024 年 11 月 29 日，中国光大集团股份公司（以下简称"光大集团"）与中 国光大实业（集团）有限责任公司（以下简称"光大实业"）签署《中国光大集 团股份公司与中国光大实业（集团）有限责任公司之股权划转暨增资协议》（嘉 事堂）及《中国光大集团股份公司与中国光大实业（集团）有限责任公司之股权 划转暨增资协议》（光大健康），将其持有的嘉事堂 14.12%股份及光大健康 100% 股份划转给光大实业。 具体内容详见公司 2024 年 12 月 2 日披露于《中国证券报》《证券时报》和 巨潮资讯网（http://www.cninfo.com.cn）上的《关于权益变动的提示性公告》 （公告编号：2024-39） 二、本次权益变动的股份过户情况 根据中国证券登记结算有限责任公司于 2025 年 4 月 23 日出具的《证券过户 登记确认书》，光大集团已于 2025 年 4 月 22 日将持有的公司 41,180,805 股股份 过户至光大实业名下，本次权益变动的股份过户登记手续已办理完毕。本次权益 变动的股份过户登记完成 ...